121
Participants
Start Date
April 1, 2013
Primary Completion Date
November 10, 2016
Study Completion Date
November 10, 2016
Blood collection
Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
New York Oncology Hematology, New York
Abramson Cancer Center, University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Waverly Hematology Oncology, Cary
Duke University, Durham
Florida Cancer Specialists, St. Petersburg
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
University of Michigan Comprehensive Cancer Center, Ann Arbor
Minnesota Oncology Hematology, Minneapolis
Mayo Clinic, Rochester
Nebraska Cancer Specialists, Omaha
Texas Oncology - Baylor, Dallas
Texas Oncology, Houston
Arizona Oncology Associates, Phoenix
Comprehensive Cancer Centers of Nevada, Henderson
Northwest Cancer Specialists, Portland
Dana-Faber Cancer Institute, Boston
Mt. Sinai Hosp., Marvette Koffler Breast Center, Toronto
Princess Margaret Hospital, Toronto
Lead Sponsor
Janssen Diagnostics, LLC
INDUSTRY